- Home
- CTRN vs ALT Comparison
CTRN vs ALT Comparison
Compare CTRN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRN | ALT |
|---|---|---|
| Founded | 1946 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 559.1M | 573.8M |
| IPO Year | 2005 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CTRN | ALT |
|---|---|---|
| Price | $55.44 | $3.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $52.00 | $17.67 |
| AVG Volume (30 Days) | 160.8K | ★ 3.3M |
| Earning Date | 06-02-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.14 | 25.37 |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $819,962,000.00 | $41,000.00 |
| Revenue This Year | $8.81 | N/A |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | $73.19 | ★ N/A |
| Revenue Growth | 8.88 | ★ 105.00 |
| 52 Week Low | $29.60 | $2.56 |
| 52 Week High | $77.91 | $6.44 |
Technical Indicators
Market Signals| Indicator | CTRN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 51.24 |
| Support Level | $41.63 | $3.18 |
| Resistance Level | $66.38 | $3.32 |
| Average True Range (ATR) | 2.96 | 0.13 |
| MACD | -1.35 | -0.01 |
| Stochastic Oscillator | 5.77 | 33.03 |
Price Performance
Historical ComparisonAbout CTRN Citi Trends Inc.
Citi Trends Inc is a differentiated off-price value retailer known for trendy fashions, great brands and amazing prices. It is the off-price retailer specifically focused on Black customers, delivering the styles, brands, and trends at amazing prices that resonate with its primary and secondary customers. Its product offering is Women's, Men's and Children's apparel, family footwear, accessories and products for the home, with a three-tiered mix of product. At the opening price point, the company offers value-focused basics for its budget-conscious customers.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.